Learning Objectives
After completing this activity, the participant will demonstrate the ability to:
- Assess the clinical and psychosocial implications caused by the effects of GHD and growth-related disorders
- Implement clinical practice guidelines for GHD and growth-related
disorders that ensure early and accurate diagnoses, testing
requirements, coding, treatment considerations, and follow-up for
optimal patient outcomes
- Employ pharmacoeconomic modeling and other decision support tools to appropriately invest resources on GH replacement therapy
- Provide accurate and appropriate counsel as part of the care team
- Provide appropriate care and counsel for patients and their families
Faculty
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
Medical Director
HumanaOne
Milwaukee, Wisconsin
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP is the National Medical Director for HumanaOne, based in Milwaukee, Wisconsin. In
his current role, Dr. Tzeel functions as a member of the executive
management team for the Individual Health Insurance Product. He
provides clinical input and expertise to the development,
implementation and actions of underwriting as well as strategic
marketing of healthier risks. In addition, Dr. Tzeel creates clinical
strategies coordinated with other clinical management processes in place
throughout the company. Specifically, he functions as the internal
subject matter expert on the topic of diabetes. Prior to his assuming
the role with HumanaOne, Dr. Tzeel was the Regional Market
Medical Officer for Humana's Wisconsin and Michigan markets. He is a
Board Certified pediatrician.
Dr. Tzeel joined Humana in March, 1999 as Medical Director for the Milwaukee market. Previously, he served as Associate Medical Director for the Health Alliance Plan in Detroit, Michigan. Dr.
Tzeel earned his Medical Degree from the University of Michigan Medical
School in Ann Arbor, MI and his Masters in Health Services
Administration from the University of Michigan School of Public Health,
also in Ann Arbor. He is a Certified Physician Executive, a
Fellow of the American College of Physician Executives and a Fellow of
the American Academy of Pediatrics.
Dr. Tzeel represents Humana on numerous external committees including
the Board of Directors of the Center for Health Value Innovation
(www.vbhealth.org) and the Board of Advisors for the Wisconsin Health
Information Exchange (www.whie.org). He had also been
appointed to the Governance Committee of the Wisconsin Relay of
Electronic Data (WIRED) for Health Board. Earlier, he served as the
Chair of the Healthcare subcommittee of the Wisconsin Partnership on
Activity and Nutrition. Dr. Tzeel is the author or co-author of multiple
papers and books including "When to Call the Doctor" (Dalmatian Press,
1999) and "The Encyclopedia of Children's Health and Wellness" (Facts on
File, 2004).
Linda Bevington, RN, BSN, CPN
Patient/Family Educator
Family Learning Center
Children's Hospital of Philadelphia
Philadelphia, PA
Linda Bevington, RN, BSN, CPN
Linda Bevington, RN, BSN, CPN is a Patient Family
Educator at Children's Hospital of Philadelphia (CHOP). She has over 15
years experience in training patients and caregivers to use various
growth hormone therapy devices. Ms. Bevington has served as faculty on
several continuing nursing and patient education programs and recently
presented a poster at the 28th Annual Pediatric Nursing
Conference on the use of video instruction to improve caregiver
education. Along with her colleagues from CHOP's Artificial Airway
Advisory Group, she received the Health Care Education Association's
Award for Excellence in Practice: Patient/Community Education for her
work to optimize education for caregivers with children with a
tracheotomy and ventilator being discharged to home care.
Pinchas Cohen, MD
Professor and Chief of Endocrinology
Mattel Children's Hospital
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
Pinchas Cohen, MD
Dr. Cohen graduated with highest honors in 1986 from
the Technion Medical School in Israel, and trained in Pediatrics,
Endocrinology and Diabetes at Stanford University until 1992. He
was an Associate Professor and Program Director at the University of
Pennsylvania and Children's Hospital of Philadelphia until 1998. He is
currently a Professor and Chief of Endocrinology at Mattel Children's
Hospital, David Geffen School of Medicine at the University of
California, Los Angeles (UCLA). He is also the associate director of the
UCSD/UCLA Diabetes/Endocrinology Research Center. He was inducted into
both the Society for Pediatric Research and the American Pediatric
Society. He is the recipient of Juvenile Diabetes
Association, American Diabetes Association, Pediatric Diabetes &
Endocrinology Society, Eli Lilly, CaPCURE, and Ross awards, and most
recently, the American Pediatric Society Best Science Award. Dr. Cohen
published over 250 papers focusing on diabetes, growth disorders,
cancer, aging, GH/IGF biology and the emerging science of humanin and
other mitochondrial peptides. He received grants from the
National Institutes of Health (NIH), FDA, and various foundations
including the Prostate Cancer Foundation. He recently received a
EUREKA-Award and the NIH-Director-Transformative RO1-Grant. He serves on
several NIH study sections and his editorial services include being an
associate editor of Pediatric Research and a member of the editorial boards of Journal of Clinical Endocrinology and Metabolism, Endocrinology, and the Journal of GH and IGF Research,
as well as being an executive officer of the GH Research society, the
IGF Society and the Endocrine Society Steering Committee.
Terri H. Lipman, PhD, CRNP, FAAN
Miriam Stirl Endowed Term Professor of Nutrition
Professor of Nursing of Children
University of Pennsylvania School of Nursing
Philadelphia, PA
Terri H. Lipman, PhD, CRNP, FAAN
Terri H. Lipman, PhD, CRNP, FAAN, is the Miriam Stirl
Endowed Term Professor of Nutrition, a Professor of Pediatric Nursing
at the University of Pennsylvania and the director of the Pediatric
Acute/Chronic and Pediatric Oncology Nurse Practitioner Programs. She is
a faculty member of the Center for Health Equities, associated faculty
in the Center for Public Health Initiatives and a Distinguished Fellow
in the Netter Center for Community Partnerships. She is the recipient of
the Lindback Award for Distinguished Teaching. Dr. Lipman is also a
pediatric nurse practitioner in the Division of Endocrinology and
Diabetes at the Children's Hospital of Philadelphia.
Dr. Lipman received her BSN from Temple University in Philadelphia, and
her MSN, PhD and CRNP from the University of Pennsylvania. After
receiving her master's degree she practiced as an advanced practice
nurse at St. Christopher's Hospital for Children. Dr. Lipman serves on
numerous professional committees. She is the co-chair of the
Surveillance Committee for the Pennsylvania Diabetes Action Plan and has
long been active in the PENS organization. She has served as Research
Chair, Grant Director and is currently the editor of the PENS column in
the Journal of Pediatric Nursing.
Dr. Lipman has published widely and has given numerous national and
international presentations. Her major areas of research have been the
epidemiology of diabetes and assessment of growth of children. The
Philadelphia Pediatric Diabetes Registry is one of only three
longstanding such registries in the United States. She and Karen Hench,
RN, MS, were co-principal investigators of a multicenter randomized,
controlled trial evaluating growth assessment
in primary care practices. That study, funded by the Genentech
Foundation for Growth and Development and by PENS, was published in the Archives of Diseases in Childhood and the Journal of Pediatric Nursing
and has received widespread coverage in the lay press. Dr. Lipman's
current research interests include racial disparities in children with
endocrine disorders, the effect of the economic distress on food choices
in adolescents, and community based participatory research. Dr.
Lipman's nurse practitioner students collaborated with inner city high
school students to screen children in the community for diabetes risk
factors. The students received a Mayoral Proclamation and Citations from
Philadelphia City Council for their service to the community.
Mark E. Molitch, MD
Professor of Medicine
Endocrinology
Northwestern University Feinberg School of Medicine
Chicago, IL
Mark E. Molitch, MD
Dr. Molitch is an endocrinologist specializing in diabetes at Northwestern Memorial Hospital. He
is also a Professor of Medicine in the Division of Endocrinology,
Metabolism, and Molecular Medicine at the Northwestern University's
Feinberg School of Medicine. His specialties include pathogenesis and
treatment of pituitary tumors as well as the treatment of diabetic
complications. Before earning his doctorate from the
University of Pennsylvania, Dr. Molitch completed a fellowship with the
University of California-Los Angeles Medical Center. He is board
certified in the areas of endocrinology, diabetes and metabolism and
internal medicine. Dr. Molitch is also devoted to serving the
underprivileged people of Bolivia as cofounder of a clinic called Centro
Medico Humberto Parra.
In addition to editing eight books and journal volumes, Dr. Molitch has
authored or coauthored more than 350 original papers, review articles,
book chapters, case reports and other publications. For many years, Dr.
Molitch was an Associate Editor of the Year Book of Endocrinology and is
an Editor of the journal, Pituitary. In 1997, Dr. Molitch was named
"Outstanding Physician Educator in the Field of Diabetes" by the
American Diabetes Association. In 2006 he was elected to the Council of
The Endocrine Society. He is currently Chair of the Clinical
Endocrinology Update 2010 program committee of the Endocrine Society.
Nancy A. Nickman, PhD, RPh
Professor of Pharmacotherapy
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, UT
Nancy A. Nickman, PhD, RPh
Dr. Nancy Nickman is a Professor of Pharmacotherapy
and Presidential Teaching Scholar in the College of Pharmacy at the
University of Utah. She received a Bachelor of Science in Pharmacy degree
from the University of Montana and graduate degrees from the University
of Minnesota in both Hospital Pharmacy (MS) and Social and
Administrative Pharmacy (PhD). She also completed a two year ASHP
Residency in Hospital Pharmacy at United and Children's Hospital in St.
Paul, Minnesota (1982-1984). Nancy served as a tenured professor from
1987-2001, and returned to the faculty as a Professor of Pharmacotherapy
in 2004 after owning her own business for five years. In 1995, she was
named a University of Utah Presidential Teaching Scholar (award merged
in 1997 with the University of Utah Distinguished Teaching Award). Her
teaching and research expertise includes patient-centered outcomes
research to improve provision and quality of patient care based on
application of industrial engineering and economic analyses.
Publications and presentations include work sampling evaluations of
institutional pharmacy services for redesign of structural and
functional activities, pre-post analyses of the impact of technology on
the practice of health professionals, simulated time-and-motion
evaluations coupled with microcost analyses of issues related to
medication preparation and administration, and simulated time-and motion
analysis of devices intended for medication self-administration.
Jointly sponsored/coprovided by the Postgraduate Institute for Medicine and Impact Education, LLC
www.impactedu.net www.pimed.com
 
The Managed Care Review Board™ – Analysis of Therapies for Growth Hormone Deficiency and Growth-Related Disorders
Supported by an educational grant from Novo Nordisk, Inc.
Estimated time to complete activity: 1.5 hours
Target Audience
- Medical Directors and Pharmacy Directors from health plans,
HMOs, integrated health systems, employers, quality organizations, and
other managed care organizations (MCOs)
- Managed care-affiliated care team members involved with patient
evaluation, education, and follow-up for growth/growth disorders
including: physicians, pharmacists, registered nurses, and case managers
Special Offering
Video demonstration of various recombinant human growth hormone (rhGH) administration devices by a nurse specialist.
Statement of Need
The treatment of children with recombinant human growth
hormone (rhGH) can be effective for increasing height toward
normalization in all indications, particularly in children with growth
hormone deficiency (GHD). Some studies have shown that children with
idiopathic short stature (ISS) and GHD suffer from stress and other
emotional and behavioral problems. Adults with GHD receiving rhGH
therapy show improvements in body composition, quality of life, and
surrogate markers for cardiovascular disease.
The treatment of GHD and growth-related disorders present distinct challenges for MCOs, payers, and affiliated providers. Balancing resource allocation with patient safety and optimal clinical outcome is paramount to payers and patients alike. Informed
decisions are needed about the optimal role of GH replacement therapy
so that patients who will benefit most are sure to receive it. This
activity will address the educational needs of the target audience to
enhance the health and well-being of many health plan patients, both
children and adults, who suffer from GHD and growth-related disorders.
Physician Accreditation Statement
This activity has been planned and implemented in accordance
with the Essential Areas and policies of the Accreditation Council for
Continuing Medical Education through the joint sponsorship of
Postgraduate Institute for Medicine and Impact Education, LLC. The
Postgraduate Institute for Medicine is accredited by the ACCME to
provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacist Accreditation Statement
Postgraduate Institute for Medicine is accredited by the
Accreditation Council for Pharmacy Education as a provider of continuing
pharmacy education.
Credit Designation
Postgraduate Institute for Medicine designates this
continuing education activity for 1.5 contact hours (1.5 CEUs) of the
Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0809-9999-13-200-H01-P)
Type of Activity: Application
For Pharmacists: Upon receipt of the completed
activity evaluation form, transcript information will be available at
www.mycpemonitor.net within 4 weeks.
Nursing Continuing Education
Credit Designation
This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.
Accreditation Statements
 Postgraduate
Institute for Medicine is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center's
Commission on Accreditation.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires
instructors, planners, managers and other individuals who are in a
position to control the content of this activity to disclose any real or
apparent conflict of interest (COI) they may have as related to the
content of this activity. All identified COI are thoroughly vetted and
resolved according to PIM policy. PIM is committed to
providing its learners with high quality CME activities and related
materials that promote improvements or quality in healthcare and not a
specific proprietary business interest of a commercial interest.
The faculty reported the following
financial relationships or relationships to products or devices they or
their spouse/life partner have with commercial interests related to the
content of this CME activity:
|
Name of Faculty or Presenter
|
Reported Financial Relationship
|
|
Albert Tzeel, MD, MHSA, CPE, FACPE, FAAP
|
Consulting Fees: Amylin Pharmaceuticals Inc.
|
| Linda Bevington, RN, BSN, CPN |
No financial interest/relationships relating to the topic of this activity |
| Pinchas Cohen, MD |
Consulting Fees: Novo Nordisk, Inc. |
| Terri H. Lipman, PhD, CRNP, FAAN |
Consulting Fees: Roche, Inc. |
| Mark E. Molitch, MD |
Consulting Fees: Novo Nordisk, Inc.
Contracted Research: Novo Nordisk, Inc. and Eli Lilly and Company |
|
Nancy A. Nickman, PhD, RPh
|
Contracted Research: Amgen Inc. and Novartis Pharmaceuticals Corporation
|
The planners and managers reported
the following financial relationships or relationships to products or
devices they or their spouse/life partner have with commercial interests
related to the content of this CME activity:
The following PIM planners and managers, Laura Excell, ND,
NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci,
PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN,
NP-C, CCRN, hereby state that they or their spouse/life partner do not
have any financial relationships or relationships to products or devices
with any commercial interest related to the content of this activity of
any amount during the past 12 months.
|
Planner:
Steven Casebeer, MBA
|
Has nothing to disclose.
|
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit
for this activity. During the period May 30, 2013 through November 30,
2014, participants must 1) read the learning objectives and faculty
disclosures; 2) study the educational activity; 3) successfully complete
the embedded questions within the activity; 4) and complete the
evaluation form. Upon completion of the full CME/CE activity, your
certificate will be made available immediately to download and print.
For Pharmacists: Upon receipt of the completed activity
evaluation form, transcript information will be available at
www.mycpemonitor.net within 4 weeks.
Media
Internet
Disclosure of Unlabeled Use
This educational activity may contain discussion of published
and/or investigational uses of agents that are not indicated by the
FDA. The planners of this activity do not recommend the use of any agent
outside of the labeled indications.
The opinions expressed in the educational activity are those
of the faculty and do not necessarily represent the views of the
planners. Please refer to the official prescribing
information for each product for discussion of approved indications,
contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly
acquired information to enhance patient outcomes and their own
professional development. The information presented in this activity is
not meant to serve as a guideline for patient management. Any
procedures, medications, or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians
without evaluation of their patient's conditions and possible
contraindications and/or dangers in use, review of any applicable
manufacturer's product information, and comparison with recommendations
of other authorities.
Hardware/Software Requirements
Google Chrome for Windows, Mac, or Linux
Internet Explorer 7.0+ for Windows
Mozilla 1.4+ for Windows, Mac, or Linux
Firefox 3.5+ for Windows, Mac, or Linux
Safari 4.0+ for Mac
Fee Information
There is no fee for this educational activity.
Questions
If you have any questions, please call (215) 619-8812 or email MCRB@impactedu.net
|
